KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Payables (2016 - 2025)

Historic Payables for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $15.3 million.

  • Inovio Pharmaceuticals' Payables rose 393.63% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 393.63%. This contributed to the annual value of $16.2 million for FY2024, which is 1837.86% down from last year.
  • Inovio Pharmaceuticals' Payables amounted to $15.3 million in Q3 2025, which was up 393.63% from $15.8 million recorded in Q2 2025.
  • Inovio Pharmaceuticals' Payables' 5-year high stood at $105.0 million during Q2 2022, with a 5-year trough of $12.9 million in Q1 2025.
  • Its 5-year average for Payables is $32.6 million, with a median of $21.3 million in 2023.
  • As far as peak fluctuations go, Inovio Pharmaceuticals' Payables soared by 24893.94% in 2022, and later tumbled by 7975.04% in 2023.
  • Inovio Pharmaceuticals' Payables (Quarter) stood at $47.6 million in 2021, then surged by 67.25% to $79.7 million in 2022, then plummeted by 75.09% to $19.8 million in 2023, then decreased by 18.38% to $16.2 million in 2024, then dropped by 5.41% to $15.3 million in 2025.
  • Its Payables was $15.3 million in Q3 2025, compared to $15.8 million in Q2 2025 and $12.9 million in Q1 2025.